Lepu Biopharma Co., Ltd. (HKG:2157)

Lepu Biopharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	853.03	401.29	426.02	669.4	155.17
Short-Term Investments	1.03	11.08	8.78	8.81	59.07
Trading Asset Securities	105.73	63.63	63.63	-	-
Cash & Short-Term Investments	959.78	475.99	498.43	678.2	214.24
Cash Growth	101.64%	-4.50%	-26.51%	216.57%	-71.86%
Accounts Receivable	66.88	45.82	37.8	3.04	-
Other Receivables	27.82	35.97	17.37	22.3	0.07
Receivables	94.71	81.79	55.17	25.34	0.07
Inventory	51.83	22.79	29.41	24.06	24.18
Prepaid Expenses	35.97	63.89	89.36	81.62	73.34
Other Current Assets	-	1.05	4.78	3.58	2.3
Total Current Assets	1,142	645.51	677.15	812.8	314.13
Property, Plant & Equipment	1,027	1,051	1,087	1,039	978.44
Long-Term Investments	397.35	114.07	126.69	122.39	137.97
Goodwill	52.64	52.64	52.64	52.64	52.64
Other Intangible Assets	448.43	382.61	381.59	398.18	422.45
Other Long-Term Assets	31.56	34.82	59.01	104.1	176.43
Total Assets	3,100	2,281	2,384	2,529	2,082

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	183.83	236.14	207.61	166.13	158.82
Accrued Expenses	40.34	34.48	32.88	32.51	23.96
Short-Term Debt	-	-	-	329.63	40.41
Current Portion of Long-Term Debt	756.32	538.41	434.3	30.36	20
Current Portion of Leases	31.97	44.36	28.34	37.17	22.91
Current Income Taxes Payable	7.48	16.91	1	1.51	1.94
Current Unearned Revenue	0.41	0.91	-	-	4
Other Current Liabilities	141.71	172.31	195.43	246.49	277.02
Total Current Liabilities	1,162	1,044	899.56	843.79	549.06
Long-Term Debt	275.55	255.94	260	290.06	232.47
Long-Term Leases	-	11.46	24.18	3.09	19.48
Long-Term Unearned Revenue	17.66	18.02	12	12	12
Long-Term Deferred Tax Liabilities	37.69	37.69	37.69	37.69	37.69
Other Long-Term Liabilities	243.92	232.27	262.17	441.79	384.29
Total Liabilities	1,737	1,599	1,496	1,628	1,235

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,804	1,711	1,659	1,659	1,532
Additional Paid-In Capital	2,904	2,578	2,420	2,420	1,842
Retained Earnings	-2,504	-2,765	-2,354	-2,331	-1,642
Comprehensive Income & Other	-817.98	-820.49	-828.8	-847.04	-894.2
Total Common Equity	1,386	702.83	896.91	900.76	836.71
Minority Interest	-23.5	-21.02	-8.21	-	10.37
Shareholders' Equity	1,363	681.8	888.7	900.76	847.08
Total Liabilities & Equity	3,100	2,281	2,384	2,529	2,082

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,064	850.16	746.82	690.3	335.26
Net Cash (Debt)	-104.05	-374.17	-248.4	-12.1	-121.03
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-0.06	-0.22	-0.15	-0.01	-0.08
Filing Date Shares Outstanding	1,804	1,711	1,659	1,659	1,659
Total Common Shares Outstanding	1,804	1,711	1,659	1,659	1,532
Working Capital	-19.77	-398.01	-222.42	-30.99	-234.93
Book Value Per Share	0.77	0.41	0.54	0.54	0.55
Tangible Book Value	885.23	267.58	462.68	449.95	361.62
Tangible Book Value Per Share	0.49	0.16	0.28	0.27	0.24
Buildings	713.19	660.23	45.55	45.55	-
Machinery	380.34	378.64	365.38	246.16	195.06
Construction In Progress	20.59	22.38	628.15	661.64	633.35
Leasehold Improvements	120.67	118.91	106.03	105.71	102.42

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 27, 2026

Data Sources Report a data error